Lan Fan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lan Fan has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Dong Guo
School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China
1 shared publication - Dongsheng Ouyang
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, People’s Republic of China
1 shared publication - Gan Zhou
Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China
1 shared publication Hai‐Tang Xie
Pharmacogenetics Research Institute, Institute of Clinical Pharmacology
1 shared publicationHan‐Wu Deng
Department of Pharmacology, School of Pharmacy, Central South University, Changsha, Hunan, China
1 shared publicationHonghao Zhou
Department of Clinical Pharmacology Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders Xiangya Hospital Central South University Changsha China
1 shared publication
Latest Publications
- 12 July 2020
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 93 (1) , e12933
The pathogenesis of cutaneous lupus erythematosus: The aberrant distribution and function of different cell types in skin lesions
Cutaneous lupus erythematosus (CLE) is an autoimmune disease with a broad range of cutaneous manifestations. In skin lesions of CLE, keratinocytes primarily undergo apoptosis. Interferon‐κ(IFN‐κ) is belonged to type I interferons (type I IFNs) and is selectively produced by keratinocytes. Recently, keratinocytes selectively produced IFN‐κ is identified to be a key to trigger type I interferon responses in CLE. Other immune cells such as plasmacytoid dendritic cells (pDCs) are identified to be relevant origin of type I interferons (type I IFNs) which are central to the development of CLE lesions and responsible for mediating Th1 cell activity. Other types of cells such as neutrophils, B cells and Th17 cells also are involved in the development of this disease. The close interaction of those cells composes a comprehensive and complicated network in CLE. In this review, we discussed the aberrant distribution and function of different cells types involved in this disease and will offer a new direction for research and therapy in the near future.
- 12 July 2020
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 93 (1) , e12933
The pathogenesis of cutaneous lupus erythematosus: The aberrant distribution and function of different cell types in skin lesions
Cutaneous lupus erythematosus (CLE) is an autoimmune disease with a broad range of cutaneous manifestations. In skin lesions of CLE, keratinocytes primarily undergo apoptosis. Interferon‐κ(IFN‐κ) is belonged to type I interferons (type I IFNs) and is selectively produced by keratinocytes. Recently, keratinocytes selectively produced IFN‐κ is identified to be a key to trigger type I interferon responses in CLE. Other immune cells such as plasmacytoid dendritic cells (pDCs) are identified to be relevant origin of type I interferons (type I IFNs) which are central to the development of CLE lesions and responsible for mediating Th1 cell activity. Other types of cells such as neutrophils, B cells and Th17 cells also are involved in the development of this disease. The close interaction of those cells composes a comprehensive and complicated network in CLE. In this review, we discussed the aberrant distribution and function of different cells types involved in this disease and will offer a new direction for research and therapy in the near future.
- 20 March 2010
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 37 (4) , 501-505
Development and validation of a simple and sensitive liquid chromatography–tandem mass spectrometry method for quantifying trimetazidine in human plasma
Summary: 1. A simple and sensitive liquid chromatography–tandem mass spectrometry (LC‐MS‐MS) method for quantifying trimetazidine in human plasma was developed and validated. Sample preparation was based on deproteinating with acetonitrile.2. Chromatography was performed on a C18 analytical column (5 μm; 150 × 2.1 mm i.d.) and the retention times for trimetazidine and cetirizine (used as the internal standard) were 1.8 and 3.0 min, respectively. The ionization was optimized using an electrospray ionization source and enhanced selectivity was achieved using tandem mass spectrometry. The calibration curve ranged from 0.1 to 200 ng/mL. The inter‐day precision, accuracy and the relative standard deviation (RSD) were all < 15%. The analyte was shown to be stable over the time‐scale of the entire procedure.3. The robustness of the method was demonstrated by the good reproducibility of the results obtained during the analysis of clinical samples.
- 20 March 2010
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 37 (4) , 501-505
Development and validation of a simple and sensitive liquid chromatography–tandem mass spectrometry method for quantifying trimetazidine in human plasma
Summary: 1. A simple and sensitive liquid chromatography–tandem mass spectrometry (LC‐MS‐MS) method for quantifying trimetazidine in human plasma was developed and validated. Sample preparation was based on deproteinating with acetonitrile.2. Chromatography was performed on a C18 analytical column (5 μm; 150 × 2.1 mm i.d.) and the retention times for trimetazidine and cetirizine (used as the internal standard) were 1.8 and 3.0 min, respectively. The ionization was optimized using an electrospray ionization source and enhanced selectivity was achieved using tandem mass spectrometry. The calibration curve ranged from 0.1 to 200 ng/mL. The inter‐day precision, accuracy and the relative standard deviation (RSD) were all < 15%. The analyte was shown to be stable over the time‐scale of the entire procedure.3. The robustness of the method was demonstrated by the good reproducibility of the results obtained during the analysis of clinical samples.